PDAP1 (PDGFA Associated Protein 1) is a protein that has been primarily recognized for its role in modulating cellular processes linked to growth factor signaling, particularly through its associations with PDGF (Platelet-Derived Growth Factor). As an adaptor protein, PDAP1 contributes to the signaling pathways that influence cell proliferation, migration, and survival, activities central to developmental processes and the maintenance of tissue homeostasis. Its function extends beyond merely binding to components of the PDGF signaling pathway; PDAP1 also participates in the organization of cellular architecture and interacts with components of the cytoskeleton, facilitating cellular responses to growth factor stimuli. The regulation of PDAP1, therefore, has implications for cellular dynamics and can impact various physiological and pathological processes, including those involved in wound healing and in the development of fibrotic conditions or proliferative disorders.
The inhibition of PDAP1 involves mechanisms that can disrupt its normal function and interaction within cellular signaling pathways. One primary method of inhibiting PDAP1 is through the use of small molecule inhibitors that can bind directly to PDAP1 or its partners, thereby preventing its interaction with PDGF or other associated signaling molecules. This inhibition can effectively reduce the downstream signaling events typically mediated by PDAP1, such as those leading to cell division and migration. Additionally, genetic approaches such as siRNA or shRNA-mediated knockdown can be employed to decrease the expression levels of PDAP1, thus diminishing its availability within the cell and its contribution to PDGF signaling pathways. Furthermore, the modulation of PDAP1 activity can also be achieved indirectly by targeting upstream regulators or downstream effectors within the signaling cascade. For example, inhibiting kinases that phosphorylate PDAP1 or other related adaptors could reduce the functional activation of PDAP1, thereby curtailing its ability to propagate signals necessary for cellular responses. Understanding these mechanisms of inhibition can provide insights into how modulation of PDAP1 activity affects cellular behavior and signal transduction pathways, particularly those related to growth factor responses and cellular dynamics. Such knowledge is crucial for deciphering the complex networks of cell signaling and the potential impact of disrupting specific components like PDAP1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Src kinase inhibitor that reduces Src family kinase activity, leading to decreased PDAP1 stability via loss of phosphorylation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR inhibitor reducing PI3K-AKT pathway signaling, thereby reducing phosphorylation and activation of PDAP1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that decreases protein synthesis, affecting PDAP1 levels by reducing its overall translation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that prevents degradation of proteins regulating PDAP1, altering its intracellular levels. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Glycolysis inhibitor that leads to reduced cellular ATP levels, affecting PDAP1-mediated cellular processes. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AKT inhibitor that prevents AKT from phosphorylating PDAP1, leading to reduced PDAP1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting AKT phosphorylation, reducing PDAP1 stability via loss of AKT-mediated phosphorylation. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
JAK2 inhibitor that affects the JAK-STAT pathway, reducing transcription factors that may upregulate PDAP1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor that impairs p38-dependent activation of PDAP1. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
AKT inhibitor that selectively inhibits AKT phosphorylation, resulting in reduced phosphorylation and activation of PDAP1. |